Total Payments
$10,376
2024 Payments
$1,682
Companies
38
Transactions
626
Medicare Patients
19,107
Medicare Billing
$1.8M
Payment Breakdown by Category
Food & Beverage$10,300 (99.3%)
Education$76.34 (0.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,300 | 617 | 99.3% |
| Education | $76.34 | 9 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,195 | 66 | $0 (2024) |
| PFIZER INC. | $953.31 | 70 | $0 (2024) |
| Amgen Inc. | $930.42 | 68 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $669.23 | 40 | $0 (2024) |
| Abbott Laboratories | $639.98 | 14 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $530.88 | 49 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $520.26 | 37 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $507.75 | 29 | $0 (2024) |
| Merck Sharp & Dohme LLC | $491.24 | 25 | $0 (2024) |
| HeartFlow, Inc. | $432.87 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,682 | 92 | Merck Sharp & Dohme LLC ($215.70) |
| 2023 | $1,114 | 54 | PFIZER INC. ($242.50) |
| 2022 | $1,152 | 67 | Novartis Pharmaceuticals Corporation ($217.06) |
| 2021 | $1,213 | 45 | HeartFlow, Inc. ($401.87) |
| 2020 | $626.99 | 33 | Janssen Pharmaceuticals, Inc ($112.43) |
| 2019 | $1,072 | 75 | Amgen Inc. ($215.48) |
| 2018 | $1,825 | 129 | Abbott Laboratories ($270.04) |
| 2017 | $1,690 | 131 | SANOFI-AVENTIS U.S. LLC ($297.53) |
All Payment Transactions
626 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: DIABETES | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.81 | General |
| Category: Cardiovascular | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $0.43 | General |
| Category: Cardiovascular | ||||||
| 11/20/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $24.34 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/16/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $17.83 | General |
| Category: Medical Device | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.60 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $2.66 | General |
| Category: Cardiovascular | ||||||
| 11/12/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $8.08 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/30/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $17.24 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/22/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $145.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $21.97 | General |
| Category: Cardiovascular Device | ||||||
| 10/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: DIABETES | ||||||
| 10/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: Cardiology | ||||||
| 10/07/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/30/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| Category: Cardiovascular | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: DIABETES | ||||||
| 09/17/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 5,144 | 6,716 | $2.2M | $471,701 |
| 2022 | 39 | 4,638 | 6,107 | $1.7M | $441,197 |
| 2021 | 41 | 4,780 | 6,662 | $1.7M | $487,590 |
| 2020 | 41 | 4,545 | 6,352 | $1.5M | $441,574 |
Total Patients
19,107
Total Services
25,837
Medicare Billing
$1.8M
Procedure Codes
171
All Medicare Procedures & Services
171 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 321 | 321 | $513,215 | $104,298 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 589 | 751 | $178,903 | $63,723 | 35.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 404 | 413 | $301,065 | $58,193 | 19.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 255 | 1,020 | $227,783 | $44,146 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 529 | 577 | $97,190 | $33,267 | 34.2% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 40 | 43 | $88,448 | $18,075 | 20.4% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 320 | 323 | $169,437 | $17,325 | 10.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 345 | 347 | $89,359 | $16,271 | 18.2% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 82 | 83 | $85,945 | $13,893 | 16.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 126 | 126 | $39,001 | $13,872 | 35.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 185 | 193 | $49,547 | $9,977 | 20.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 71 | 71 | $49,997 | $9,528 | 19.1% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 57 | 57 | $48,927 | $9,091 | 18.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 78 | 86 | $30,293 | $8,497 | 28.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 837 | 882 | $45,326 | $8,407 | 18.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 77 | 77 | $15,953 | $5,521 | 34.6% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 26 | 26 | $23,161 | $4,631 | 20.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $13,454 | $3,323 | 24.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 53 | $9,868 | $3,210 | 32.5% |
| 93459 | Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | Facility | 2023 | 16 | 17 | $19,967 | $2,972 | 14.9% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2023 | 15 | 15 | $12,616 | $2,216 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $5,701 | $1,910 | 33.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 37 | 236 | $9,657 | $1,833 | 19.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 20 | $5,354 | $1,762 | 32.9% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 19 | 20 | $7,859 | $1,628 | 20.7% |
About Dr. Raul Santos, MD
Dr. Raul Santos, MD is a Cardiovascular Disease healthcare provider based in Grapevine, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013926039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raul Santos, MD has received a total of $10,376 in payments from pharmaceutical and medical device companies, with $1,682 received in 2024. These payments were reported across 626 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($10,300).
As a Medicare-enrolled provider, Santos has provided services to 19,107 Medicare beneficiaries, totaling 25,837 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 171 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Grapevine, TX
- Active Since 08/07/2006
- Last Updated 09/18/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1013926039
Products in Payments
- ENTRESTO (Drug) $962.61
- ELIQUIS (Drug) $915.29
- PRALUENT (Drug) $549.32
- XARELTO (Drug) $520.26
- VERQUVO (Drug) $491.24
- Repatha (Biological) $480.98
- Corlanor (Drug) $438.10
- FFRct (Device) $432.87
- LifeVest (Device) $409.01
- JARDIANCE (Drug) $360.97
- Vascepa (Drug) $309.91
- VYNDAQEL (Drug) $294.49
- Perclose ProGlide suture mediated closure system (Device) $270.04
- LEQVIO (Drug) $232.01
- Edarbi (Drug) $219.79
- NORTHERA (Drug) $210.05
- CAMZYOS (Drug) $194.01
- FARXIGA (Drug) $191.88
- BRILINTA (Drug) $187.32
- Impella (Device) $186.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Grapevine
John Osborne, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M
Dr. Vikas Jain, M.d, M.D
Cardiovascular Disease — Payments: $374,314
Cardiovascular Disease $374,314
Dr. Paul Bhella, M.d, M.D
Cardiovascular Disease — Payments: $294,139
Cardiovascular Disease $294,139
Dr. John Lawson, Md, MD
Cardiovascular Disease — Payments: $7,403
Cardiovascular Disease $7,403
Dr. Amyn Malik, Md, MD
Cardiovascular Disease — Payments: $4,421
Cardiovascular Disease $4,421
Dr. Richard Feingold, D.o, D.O
Cardiovascular Disease — Payments: $3,790
Cardiovascular Disease $3,790